Skip to main content
AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%AAPL-0.36%MSFT+0.70%NVDA+3.73%GOOGL-1.24%AMZN+0.68%TSM-3.68%SPCX+3.16%AVGO+2.46%META+0.62%TSLA+0.87%LLY-1.13%BRK-B-1.03%WMT-0.69%JPM-2.44%SKHY+0.35%AMD-0.17%MU+3.96%V-2.27%XOM+0.20%JNJ-1.36%MA-2.41%ASMLa-5.34%ABBV-0.59%COST-0.33%1398.HK-0.99%0700.HK-3.69%KO-0.69%CVX-0.47%PG-0.75%CSCO+0.62%0939.HK-0.84%UNH-5.42%ORCL-3.38%3988.HK-0.63%BAC-1.28%HD-2.45%GE+0.38%0857.HK-0.38%1816.HK-2.30%1288.HK-0.86%0005.HK-1.42%PM-0.85%NVS-0.67%HSBA.L-1.95%MS-1.10%INTC-0.54%AZN-0.95%AMAT-0.29%AP2d-4.07%TXN+0.56%AUDJPY-0.68%NZDJPY-0.65%AUDUSD-0.57%NZDUSD-0.51%GBPAUD+0.49%GBPNZD+0.46%EURJPY-0.44%GBPTRY+0.41%CHFJPY-0.39%CADJPY-0.36%AUDCAD-0.33%GBPHKD+0.32%EURUSD-0.31%AUDCHF-0.30%NZDCAD-0.30%USDCHF+0.29%GBPMXN-0.28%EURAUD+0.26%NZDCHF-0.25%EURGBP-0.24%GBPCHF+0.24%USDCAD+0.23%EURNZD+0.21%GBPJPY-0.19%USDTHB-0.18%GBPCAD+0.16%USDTRY+0.16%USDILS+0.16%USDJPY-0.14%USDCNH-0.10%USDDKK+0.10%EURCNH-0.08%EURSGD-0.07%NZDMXN+0.07%EURCAD-0.07%NZDSGD+0.07%CHFSGD-0.06%GBPUSD-0.05%AUDNOK+0.05%SGDJPY+0.05%AUDNZD-0.05%CADCHF+0.05%USDCOP-0.04%USDMXN+0.03%USDSGD+0.02%AUDSGD+0.01%EURCHF-0.01%USDHKD+0.01%GBPSGD-0.01%USDZAR0.00%USDNOK0.00%PLNJPY0.00%GBPZAR0.00%USDSEK0.00%USDPLN0.00%NOKJPY0.00%EURHKD0.00%EURPLN0.00%EURCZK0.00%EURSEK0.00%EURZAR0.00%EURNOK0.00%AUDDKK0.00%CHFSEK0.00%CHFNOK0.00%EURDKK0.00%XAUUSD-0.47%GAUUSD-0.46%XNGUSD+0.46%XPTUSD-0.39%GAGUSD-0.36%XAGUSD-0.36%HG1-0.11%USOIL-0.08%COTTON0.00%COFFEE0.00%COCOA0.00%W10.00%BTCUSD-0.19%ETHUSD+58.05%USDTUSD-0.01%XRPUSD+57.05%SOLUSD+65.46%TRXUSDT+0.95%ZECUSDT+6.50%XMRUSDT+3.02%DOGEUSD+59.04%LINKUSD+1.44%XLMUSD+2.65%BCHUSDT+1.44%LTCUSD+50.36%UNIUSD+2.27%TONUSD+63.46%SUIUSD+2.10%HBARUSDT+1.13%TAOUSDT+3.44%AAVEUSD+3.57%ONDOUSDT+0.85%ICPUSDT-8.30%DOTUSDT+1.18%WLDUSDT+2.24%ARBUSDT+0.63%INJUSDT+7.34%ATOMUSDT-0.39%STXUSDT+5.51%PYTHUSDT+2.05%TIAUSDT+0.91%FETUSDT+0.61%SEIUSDT+1.04%JUPUSDT+8.18%GRTUSDT+4.71%OPUSDT-2.36%IOTAUSDT+3.17%POLUSDT+4.01%WIFUSDT+1.17%AXSUSDT+1.56%EOSUSDT+2.67%FARTCOINUSDT-1.22%IMXUSDT+2.00%GALAUSDT-1.23%DYDXUSDT+2.29%ORDIUSDT+0.10%NOTUSDT+1.77%RONINUSDT+2.00%

AbbVie lifts 2026 profit outlook on Q3 growth

NEWS

October 30, 2026 at 12:22 UTC

3 min read
Unbranded pharmaceutical vials on a production line reflecting strong AbbVie earnings and raised ABBV 2026 outlook

Key Points

  • 01AbbVie (ABBV) raised 2026 adjusted EPS guidance to $13.95-$13.99
  • 02Q3 2026 net revenue rose 10.3% to $17.404 billion
  • 03Immunology revenue grew 16.3%, led by Skyrizi and Rinvoq
  • 04Lower IPR&D and milestone expenses sharply boosted earnings

Guidance raised after strong third-quarter performance

AbbVie lifted its 2026 adjusted diluted earnings per share guidance to a narrower range of $13.95 to $13.99 after a solid third quarter. The new forecast incorporates a $0.69-per-share impact from acquired in-process research and development and milestone expenses booked through the third quarter. Both ends of the full-year EPS range were increased as the company tightened its outlook following the latest results.

The company’s decision to raise guidance follows a quarter in which profit expanded much faster than revenue. Management highlighted that reduced spending on acquired IPR&D and milestones, combined with continued strength in key growth franchises, underpinned the improved earnings outlook for 2026.

Q3 revenue and earnings momentum

On an adjusted basis, diluted EPS reached $3.82, up from $1.86 in the prior-year period, while GAAP diluted EPS rose to $2.37 from $0.10. On an operational, constant-currency basis, revenue grew 10.5%, closely matching the reported growth rate.

Profitability metrics also strengthened. GAAP gross margin improved to 75.4%, and the GAAP operating margin reached 36.0%. The adjusted operating margin rose to 48.7%. Net income attributable to AbbVie increased to $4.218 billion, compared with $186 million in the third quarter of 2025.

Immunology leads sales growth

Immunology remained AbbVie’s largest growth engine in the quarter. Within this portfolio, Skyrizi sales increased 22.7% to $5.78 billion, exceeding analyst expectations, while Rinvoq revenue grew 23.9% to $2.71 billion. These gains helped offset a 31.2% decline in Humira revenue amid ongoing biosimilar competition.

The strength of Skyrizi and Rinvoq, together with growth in the neuroscience franchise, more than compensated for weaker trends in other areas. Neuroscience revenue climbed 19% to $3.39 billion, supported by products such as Botox Therapeutic and Vraylar.

Cost profile and IPR&D trend support earnings

AbbVie’s earnings improvement was amplified by a sharp reduction in acquired IPR&D and milestone expenses. These costs dropped to $216 million in the third quarter of 2026 from $2.680 billion a year earlier, lessening their drag on earnings. The prior-year quarter also included an $847 million impairment of intangible assets that did not recur in 2026.

On a GAAP basis, selling, general and administrative expenses represented 23.5% of revenue, versus 21.2% on an adjusted basis. Research and development expenses accounted for 14.7% of revenue on a GAAP basis and 13.9% on an adjusted basis. Adjusted net income was $6.795 billion, compared with GAAP net income attributable to AbbVie of $4.218 billion.

Pipeline and Apogee acquisition outlook

AbbVie continued to invest in its pipeline alongside the improved financial performance. Phase 3 results for lutikizumab in hidradenitis suppurativa met the primary endpoint, and regulatory submissions are planned for the second half of 2027. The company also submitted a biologics license application for etentamig in relapsed or refractory multiple myeloma.

In June, AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics, adding experimental treatments for eczema and asthma. The transaction is expected to weigh on profit through 2027 before contributing to earnings in 2032, reflecting the long development and commercialization timelines associated with the acquired programs.

Key Takeaways

  • 01AbbVie (ABBV)’s higher 2026 EPS guidance is underpinned by double-digit revenue growth and significantly improved margins in the latest quarter.
  • 02Immunology products Skyrizi and Rinvoq are central to offsetting Humira’s decline and now anchor a large, fast-growing revenue base.
  • 03A sharp drop in acquired IPR&D and milestone expenses has become a major driver of earnings leverage, magnifying the impact of sales growth.
  • 04Pipeline progress and the Apogee acquisition show AbbVie (ABBV) deploying capital into future therapies while accepting a near-term drag on profit for potential long-term gains.

AbbVie lifts 2026 profit outlook on Q3 growth | Trading Dashboard